Table 2.

Serum IgG to capsular polysaccharides of S. pneumoniae^*

		Serotype
		4	6B	9V	14	18C	19F	23F
Group 1 (PPV followed by PCV)
Baseline	n†=33	0.22	0.76	0.61	1.79	0.64	2.32	0.37
4–8 wk post-PPV	n=34	0.77	1.81	1.37	5.43	2.36	4.55	1.09
6 mo post-PPV	n=21	0.32	0.74	0.61	1.75	1.05	2.59	0.40
4–8 wk post-PCV	n=22	0.95	1.09	1.18	3.73	1.80	3.53	1.13
6 mo post-PCV	n=14	0.53	0.79	0.72	2.31	0.96	2.30	0.63
Group 2 (PCV followed by PPV)
Baseline	n=29	0.23	0.65	0.59	2.23	0.93	2.04	0.44
4–8 wk post-PCV	n=32	0.80	1.71	2.26	5.66	2.93	3.72	2.36
6 mo post-PCV	n=19	0.59	1.21	2.22	5.66	2.20	3.46	2.27
4–8 wk post-PPV	n=19	1.01	2.80	3.13	7.85	3.44	5.59	3.86
6 mo post-PPV	n=12	0.41	0.88	1.47	3.99	1.57	2.76	1.25

^*Data are presented as geometrical mean IgG (µg/ml) at each stage of study for patients who received pneumococcal polysaccharide vaccine (PPV) followed by protein-conjugate pneumococcal vaccine (PCV) (Group 1) or those who received PCV followed by PPV (Group 2).

^†n= numbers of subjects at each time point. Apparent discrepancies in the numbers of subjects at different time points reflect either (a) the loss or contamination of some sera; or (b) the fact that some patients miss one follow-up appointment but return for another, for example, failing to return for a 4–8 wk follow up serum but returning at 6 months to provide serum and receive a second vaccination.